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Abstract Small interfering RNA duplexes (siRNA) induce
gene silencing in various eukaryotic cells, although usually in
an incomplete manner. Using chemically synthesized siRNAs
targeting the HIV-1 co-receptor CXCR4 or the apoptosis-induc-
ing Fas-ligand (FasL), co-transfection of cells with two or more
siRNA duplexes targeting di¡erent sites on the same mRNA
resulted in an enhanced gene silencing compared with each sin-
gle siRNA. This was shown in the down-regulation of protein
and mRNA expression, and functionally in the inhibition of
CXCR4-mediated HIV infection and of FasL-mediated cell ap-
optosis. Transfection e⁄ciency determined for the FasL-speci¢c
siRNAs was dose-dependent and varied among the siRNAs
tested, but was not the main reason for the enhanced gene
silencing.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: RNA interference; Small interfering RNA;
Gene silencing; CXCR4; Fas-ligand; HIV infection
1. Introduction
In 1998, Fire and coworkers reported that double-stranded
RNA (dsRNA) introduced into C. elegans blocked gene ex-
pression by a process of sequence-speci¢c, post-transcriptional
gene silencing (PTGS), which they termed RNA interference
(RNAi) [1]. Since then, gene silencing by dsRNA has been
established in plants, invertebrates, vertebrates and in mam-
mals [2].
The long dsRNA introduced into cells is cut by the RNase
III-related nuclease Dicer into short (21^25 nucleotides (nt))
interfering RNAs (siRNA). These siRNAs are incorporated
into a multiprotein RNA-induced silencing complex (RISC),
where the siRNA duplex is unwound, leaving the antisense
strand to guide RISC to its homologous mRNA targets for
endonucleolytic cleavage [3^5]. The discovery of RNAi and
siRNA, as well as its successful application, provides a power-
ful tool to target genes for de-activation. Recently, chemically
synthesized siRNA duplexes with a length of 21^23 nt were
shown to down-regulate the expression of endogenous and
heterologous genes in various cells including cells of human
origin [6].
We used speci¢c siRNAs to down-regulate CXCR4 in
HeLa cells and Fas-ligand (FasL) in HEK293 cells. CXCR4,
a co-receptor for HIV-1, is necessary for HIV-1 (X4 or R5X4
isolates) to enter the T cells [7], while FasL, a member of the
TNF superfamily, plays an important immune-regulatory role
by inducing apoptosis [8]. We provide evidence that in both
systems the use of two or more speci¢c siRNAs signi¢cantly
improved the gene silencing e¡ect induced by a single siRNA.
Investigating the mechanism we found that the transfection
e⁄ciency varied among the di¡erent siRNAs, was siRNA
dose-dependent but not the main reason for the enhanced
gene silencing e¡ect observed.
2. Materials and methods
2.1. siRNA preparation
21-nt sense and antisense RNA oligomers targeting against CXCR4
mRNA or the FasL mRNA were designed based on the optimal
regions found with phosphorothioate-modi¢ed antisense oligonucleo-
tides; their locations and sequences are shown in Table 1. All siRNA
strands were synthesized and IE-HPLC-puri¢ed by Qiagen AG (Basel,
Switzerland), mixed in equimolar ratios and annealed [6]. To evaluate
the transfection e⁄ciency, 3P-rhodamine-labeled FasL-speci¢c siRNAs
were used.
2.2. Cells and transfection
The HeLa CD4- and CXCR4-expressing reporter cell line SX22-1
(stably transfected CD4 expressing plasmid and carrying a lacZ gene
under the control of HIV-1 LTR), Hut/4-3 (constitutively producing
HIV-1), the FasL-expressing human embryonic kidney 293 cells,
HEK293-005, and BALB/c B-cell lymphoma A20 GFP, were cultured
as described elsewhere [9,10]. SX22-1 or HEK293 cells were trans-
fected for 48 h with siRNA duplexes, alone or in combinations, in
the presence of the carrier LipofectAMINE 2000 Reagent (Gibco)
according to the manufacturer’s protocol. Concentrations of siRNAs
were expressed as ¢nal concentrations in the cell culture medium.
2.3. Flow cytometry
At 2 days post-transfection, CXCR4 or FasL protein expression
was stained with mouse anti-human CXCR4 (12G5) or mouse anti-
human FasL (G247-4) monoclonal antibody (BD Bioscience, Basel,
Switzerland) and analyzed with a FACSCalibur £ow cytometer (BD
Bioscience). 10 000^20 000 cells were investigated. Data were pro-
cessed with the Cell Quest software [10].
2.4. TaqMan real-time reverse-transcription polymerase chain reaction
(RT-PCR)
Down-regulation of FasL mRNA was determined by quantitative
real-time RT-PCR, standardized by the corresponding GAPDH inter-
nal control [10]. For CXCR4 mRNA, the following primers and Taq-
Man probes were applied: CXCR4 sense 5P-TGATG TGTGT
CTAGG CAGGA CCT-3P, CXCR4 antisense 5P-CACTA CACGC
TCTGG AATGT TCA-3P, CXCR4 probe 5P-(FAM) TTCTT
AGTTG CTGTA TGTCT CGT (TAMRA)-3P.
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2.5. Prevention of HIV infection
At 2 days post-transfection with 20 nM siRNA-A, a combination of
siRNA duplexes or control siRNA-1, HeLa SX22-1 reporter cells
were cultured with 300 Wl of high-titer virus Hut/4-3 supernatant
(500 000 HIV copies/ml) for 1.5 days, which permits cellular HIV-1
infection and LacZ reporter gene expression. After ¢xation with glu-
taraldehyde/formaldehyde (0.1%/0.7%) in phosphate-bu¡ered saline
(PBS) for 5 min, cells were stained by X-Gal for L-galactosidase
enzyme [9].
2.6. Apoptosis induction by FasL
At 2 days post-transfection with FasL-speci¢c siRNA duplexes or
their combination, FasL-expressing HEK293 cells were washed three
times with PBS and then co-cultured with the Fas-apoptosis reporter
cells A20 GFP at a ratio of 1:2 (e¡ector: reporter cells) in FACS
tubes overnight. After washing with PBS, the percentage of apoptotic
A20 GFP cells was determined by £ow cytometry [10].
3. Results
3.1. Down-regulation of CXCR4 and FasL with
sequence-speci¢c siRNA duplexes
CXCR4-expressing HeLa SX22-1 cells were separately
transfected with either 50 nM of siRNA-A, siRNA-B, siR-
NA-C or the control (FasL) siRNA-1. The inhibitory e¡ect
on CXCR4 expression was determined by £ow cytometry on
the protein level and by TaqMan real-time RT-PCR on the
mRNA level. As shown in Fig. 1a,b, all three speci¢c siRNA
duplexes down-regulated CXCR4 gene expression (siRNA-A
evoked the highest inhibition, 73% at the protein, 79% at the
mRNA level), whereas the control siRNA-1 did not. Simi-
larly, FasL-expressing HEK293 cells were transfected with
20 nM of siRNA-1, siRNA-2, siRNA-3 or the control
(CXCR4) siRNA-A. Fig. 1a,c shows that all three FasL-spe-
ci¢c siRNA duplexes inhibited FasL expression at the protein
and mRNA level, whereas the control siRNA-A did not.
These data show that the inhibition induced by these siRNAs
is sequence-speci¢c.
3.2. Dose-dependent down-regulation of CXCR4/FasL
expression by siRNA duplexes
Titration experiments with graded concentrations of
CXCR4-speci¢c siRNA duplexes (siRNA-A, -B and -C, Fig.
2a) or FasL-speci¢c siRNA duplexes (siRNA-1, -2 and -3,
Fig. 2b) demonstrate that siRNA-mediated down-regulation
of CXCR4 or FasL expression was dose-dependent. The max-
imal CXCR4 inhibitory e¡ect was observed at 20 nM for
siRNA-A, at 40 nM for siRNA-B and at 80 nM for siR-
NA-C (Fig. 2a). Further increasing the concentration did
not increase the inhibitory potential of all three CXCR4-spe-
ci¢c siRNA duplexes tested. The situation for FasL is similar
(Fig. 2b). All three FasL-speci¢c siRNA duplexes reached
their optimal activities at V20^50 nM, but siRNA-1 and
siRNA-2 were less potent than siRNA-3. It was tested
whether the lower inhibition by siRNA-1 and -2 was due to
a lower transfection e⁄ciency. Using rhodamine-labeled
FasL-speci¢c siRNAs, it was found that transfection e⁄ciency
was also dose-dependent and to some extent, but consistently,
varied among the di¡erent siRNAs (Fig. 2c). Although there
was some correlation between inhibition and transfection e⁄-
ciency concerning the siRNA concentration, there was no di-
Fig. 1. Down-regulation of CXCR4 and FasL expression by siRNA. a: FACS histograms of HeLa cells separately transfected with 50 nM of
CXCR4-speci¢c siRNA-A, -B, -C and siRNA-1 as control (left column), and HEK293 cells transfected with 20 nM of FasL-speci¢c siRNA-1,
-2, -3 and the control siRNA-A (right column). CXCR4 (panel b) and FasL (panel c) mRNA expression was quanti¢ed by TaqMan real-time
RT-PCR (black bar) and compared with protein expression measured by FACS (white bar). All results represent the mean of triplicate experi-
ments including standard deviations (S.D.).
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rect correlation between the number of transfected cells and
the gene silencing potency of the di¡erent siRNAs used. For
example, although siRNA-2 and -3 showed similar transfec-
tion e⁄ciency, they greatly di¡ered in their gene silencing
activity.
3.3. Enhanced e¡ect of multiple speci¢c siRNA duplexes
The above data con¢rm published results that gene silenc-
ing with a single chemically synthesized siRNA is incomplete
[6,11]. Therefore, it was further tested whether co-transfection
of cells with a combination of two or more speci¢c siRNA
duplexes targeting di¡erent regions of mRNA could increase
the inhibitory e¡ect induced by any single siRNA duplex.
As 20 nM siRNA-A demonstrated the highest inhibitory
e¡ect (V70%) on CXCR4 expression, this concentration
was taken as a reference for the combination experiments.
Indeed, higher inhibition was observed when cells were treated
with combinations of speci¢c siRNA duplexes (Fig. 3a). Up to
90% inhibition of CXCR4 protein expression was reached
when cells were co-transfected by a combination of siRNA-
A, siRNA-B and siRNA-C. This higher inhibition is not due
to an increase of the total concentration of siRNAs used (see
Fig. 2a, or A+A in Fig. 3a). As shown in Fig. 3a, A plus B
expressed a higher inhibitory activity than A plus C in accor-
dance with the fact that B alone had a higher activity than C.
Moreover, A plus 60 nM B had a higher activity than A plus
40 nM B or A plus 20 nM B. Finally, a combination of three
siRNA duplexes exhibited a higher inhibitory activity than
two. These data clearly suggest that each siRNA duplex con-
tributes to the total activity in the combination. The enhanced
inhibitory e¡ect of multiple speci¢c siRNA duplexes was con-
¢rmed at the mRNA level by TaqMan real-time RT-PCR and
was also detected at lower concentrations of CXCR4-speci¢c
siRNA duplexes (data not shown). Of interest, control si-
Fig. 2. Dose-dependent down-regulation of CXCR4 and FasL ex-
pression by siRNA. HeLa cells (panel a) or HEK293 cells (panel b)
were separately transfected with graded concentrations of the si-
RNA duplexes indicated for 48 h. c: Transfection e⁄ciency was de-
termined by FACS analysis of HEK293 cells transfected with rhoda-
mine-labeled siRNA-1, -2, -3 at the FL-2 channel. Down-regulation
of CXCR4/FasL expression was measured by FACS at the FL-1
channel. The results of siRNA-A and siRNA-3 represent the mean
of triplicate experiments including standard deviations (S.D.).
Fig. 3. Enhanced gene silencing induced by a combination of specif-
ic siRNA duplexes. a: HeLa cells were transfected with 20 nM or
the indicated concentrations of siRNA duplexes alone or in combi-
nations and CXCR4 down-regulation was measured by FACS. The
relative inhibition was normalized to that of 20 nM siRNA-A alone,
which was set to 1. The inhibition of s 1 re£ects its higher inhibi-
tory activity than 20 nM siRNA-A. b: FasL down-regulation (black
bars) and transfection e⁄ciency (white bars) in HEK293 cells was
measured as described in the legend to Fig. 2. All results represent
the mean of triplicate experiments including standard deviations
(S.D.).
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RNA-1 co-transfected with siRNA-A resulted in a reduced
gene silencing e¡ect of the speci¢c siRNA-A (Fig. 3a). This
competing e¡ect is highly reproducible and also valid for oth-
er siRNA combinations (data not shown). The mechanism of
this competition is not yet known, but other groups have
made similar observations [11,12].
To exclude that the enhanced inhibition by a combination
of siRNAs was a CXCR4-speci¢c e¡ect, similar experiments
Fig. 4. Functional assay for CXCR4 and FasL. a: Inhibition of CXCR4-mediated HIV-1 infection in vitro: Photomicrograph of L-gal-stained
HeLa SX22-1 cells, which were treated with 20 nM siRNA-A, a combination of speci¢c siRNAs (A+B+C), control siRNA-1 or PBS, followed
by infection with high-titer HIV-1. b: Quanti¢cation of HIV-infected cells : For each condition three non-overlapping cell areas were randomly
chosen and the number of blue cells was counted. The number of infected cells is signi¢cantly di¡erent between siRNA-A and the siRNA com-
bination treatment (*P=0.026; two-sample t-test). c : Inhibition of the apoptosis-inducing function of FasL: A20 GFP cells were cultured over-
night with HEK293 cells untransfected or transfected with 20 nM siRNA-1, siRNA-2 or their combination. The percentage of apoptotic A20
cells was determined by FACS analysis. All results represent the mean of triplicate experiments including standard deviations (S.D.).
Table 1
Sequences and locations of siRNAs
Name Sequence Location
siRNA-A 5P-GCGGCAGCAGGUAGCAAAGTTTTCGCCGUCGUCCAUCGUUUC-5P CXCR4 5PUTRa
siRNA-B 5P-AUGGAGGGGAUCAGUAUAUTTTTUACCUCCCCUAGUCAUAUA-5P CXCR4 start codonb
siRNA-C 5P-CUGGGCAGUUGAUGCCGUGTTTTGACCCGUCAACUACGGCAC-5P CXCR4 codon regionb
siRNA-1 5P-AGUGGCCCAUUUAACAGGCTTTTUCACCGGGUAAAUUGUCCG-5P FasL splicing sitec
siRNA-2 5P-CAGGCAAGUCCAACTCAAGTTTTGUCCGUUCAGGUUGAGUUC-5P FasL splicing sitec
siRNA-3 5P-GGGCUGUACUUUGUAUAUUTTTTCCCGACAUGAAACAUAUAA-5P FasL splicing sitec
aAccording to Homo sapiens CXCR4 gene, Accession No. AF005058.
bAccording to Homo sapiens CXCR4 mRNA, Accession No. NM-003467.
cAccording to Homo sapiens FasL mRNA, Accession No. D38122.
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were performed with siRNAs targeting FasL. HEK293 cells
were transfected with di¡erent concentrations of FasL-speci¢c
siRNA-1 and siRNA-2, either alone or in combination; both
of them singly induce a suboptimal inhibition. Co-transfection
of cells with both siRNA-1 and siRNA-2 evoked an enhanced
inhibition of FasL expression at optimal concentrations (each
25 nM) (Fig. 3b), whereas at lower or higher doses the en-
hanced inhibitory e¡ect was less marked (Fig. 3b). In analogy
to CXCR4, the enhanced FasL gene silencing detected was
not due to the increase of the doses used, as the inhibition
of the corresponding concentrations of 20, 50 or 100 nM
siRNA-1 or siRNA-2 alone was below that of the combined
concentrations. Transfection e⁄ciency was not a major reason
for the enhanced inhibition, as the percentages of transfected
cells by the combination of siRNA-1 and -2 lay between the
single siRNAs (Fig. 3b).
3.4. Enhanced inhibition of HIV-1 infection in vitro by multiple
speci¢c siRNA duplexes
It was tested whether the enhanced e¡ect of multiple spe-
ci¢c siRNA duplexes could also be detected in the prevention
of HIV-1 infection. At 2 days post-transfection with siRNA-
A, a combination of three CXCR4-speci¢c siRNA duplexes or
control siRNA-1, cell-free high-titered HIV-1 culture super-
natant was added to SX22-1 cells. LacZ reporter gene expres-
sion (as an indicator of HIV-1 infection) was measured 1.5
days later. As illustrated in Fig. 4a and con¢rmed by quanti-
¢cation of the infected cells by counting (Fig. 4b), the combi-
nation of three siRNAs prevented the in vitro infection of
SX22-1 cells by HIV-1 more e⁄ciently than siRNA-A alone.
Moreover, the number of infected cells (blue stain by X-gal)
not only decreased, but the few infected cells also showed a
weaker blue staining, which is concordant with a lower level
of Tat expression and a delayed infection [9].
3.5. Enhanced inhibition of the apoptosis-inducing function of
FasL
FasL-expressing HEK293 cells, transfected with 20 nM si-
RNA-1 or siRNA-2 or their combination for 2 days, were co-
cultured overnight with the apoptosis reporter A20GFP cells,
followed by the determination of apoptosis by £ow cytometry.
Fig. 4c demonstrates that the siRNA combination inhibited
FasL-mediated apoptosis better than each of the siRNA du-
plexes alone, con¢rming the enhanced inhibitory e¡ect be-
tween speci¢c siRNA duplexes in a functional assay.
4. Discussion
SiRNA duplexes targeting distinct sites on the same mRNA
usually express di¡erent silencing e⁄ciency [2,11]. Recently,
Holen et al. reported that only a few siRNAs were e¡ective
in gene silencing and siRNA e⁄cacy was highly dependent on
target position, suggesting that accessible siRNA target sites
may be rare in some human mRNAs [11]. In agreement with
the above observations, we found di¡erent inhibitory activities
of our siRNAs targeting CXCR4 or FasL mRNA.
Titration experiments demonstrated that the siRNA du-
plexes tested did not completely silence the gene of interest,
which is consistent with observations made by other groups
[6,11]. Indeed, each siRNA duplex tested (CXCR4- and FasL-
speci¢c siRNA duplexes) exhibited a maximal gene silencing
ranging from about 20% to 70%. Possible reasons for the
incomplete inhibition could be the e⁄ciency of siRNA trans-
fection and/or the half-life of the target protein. Using rhoda-
mine-labeled FasL-speci¢c siRNAs, transfection e⁄ciency was
determined and found to be dose-dependent and to some ex-
tent di¡erent among the siRNAs tested. Whereas the number
of transfected cells and the inhibition partially correlated re-
garding the siRNA concentrations used, there was no clear
correlation between transfection e⁄ciency and gene silencing
among the siRNAs tested. For example, siRNAs expressing a
similar transfection e⁄ciency substantially di¡ered in their
gene silencing capacity.
As a single siRNA inhibits expression of the target gene
only incompletely, it is important to ¢nd ways to increase
the inhibition. When two or more speci¢c siRNA duplexes
were co-transfected into the reporter cells, higher inhibition
of gene expression was observed in two entirely di¡erent sys-
tems, i.e. CXCR4 and FasL. Holen et al. [11] did not see
synergism between two or three siRNAs in another system,
but no data were provided. Apart from the di¡erent gene
target utilized, it is possible that the concentrations used are
critical, as in our hands the cooperation of siRNAs is only
optimal within a certain dose range (Fig. 3b).
The underlying mechanism of the enhanced gene silencing
with multiple speci¢c siRNA duplexes is unknown. Transfec-
tion e⁄ciency can be excluded as the main reason (Fig. 3b).
Possible but still unproven explanations are: (a) SiRNA anti-
sense binding may change the secondary structure of mRNA
[13,14], opening new sites accessible for other siRNAs; (b)
two or more siRNA duplexes may increase the overall possi-
bility of target mRNA to be accessed and digested.
Our data demonstrate an enhanced gene silencing with mul-
tiple speci¢c siRNAs not only at the protein or mRNA ex-
pression level, but also at the functional level, evoking a high-
er inhibition of HIV infection and a stronger reduction of
FasL-mediated apoptosis than single siRNA. RNAi and si-
RNA have provided new promises to treat gene-mediated
disorders or viral infections. From our results, siRNA can
e⁄ciently inhibit HIV-1 infection of cells in vitro through
down-regulating CXCR4 expression, supporting observations
made by other groups [15^17]. CXCR4 is an ideal target, as it
not only prevents viral entry but is also far less sensitive to
mutation compared to the viral gene and is independent of
drug pressure [7,18]. FasL plays an important immune-regu-
latory role, and it is also discussed as a critical molecule for
immune evasion of some tumors [8]. Currently, studies try to
apply expression of siRNA in vivo [15,17,19]. Therefore, the
stable expression of multiple siRNA duplexes in vivo may not
only make the FasL immune evasion hypothesis testable but
may also help to pave the way for a clinical application to
prevent HIV-1 infection [20,21]. Moreover, the same strategy
could be applied to other human diseases.
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